The Drug of Abuse Testing Market is an increasingly vital industry, driven by the need to combat the global crisis of substance abuse. With a market value of around USD 5.0 billion in 2023, the sector is forecast to reach USD 8.9 billion by 2033, growing at a CAGR of 6.0%. This expansion is a direct result of several key factors, including stricter laws and regulations mandating drug testing in various sectors. The market is also propelled by the growing need for medical screening to identify and treat individuals with substance use disorders, as well as to monitor those undergoing pain management therapies. The ongoing opioid crisis has been a particularly powerful driver, creating an urgent demand for rapid and accurate opioid detection tests. Furthermore, technological advancements are making testing more accessible and convenient, with the development of point-of-care and at-home testing kits that provide quick results. For a detailed report on these trends, please refer to the Drug of Abuse Testing Market.
The market is segmented by drug type, with opioids and amphetamines being major contributors to market growth. The opioid segment, in particular, is expanding rapidly due to the widespread crisis and the need for frequent monitoring in clinical settings. The amphetamine segment is also significant, driven by the illicit use of stimulants and the need for testing in both workplace and forensic applications, highlighting the diverse range of substances being screened.